股本结构
单位：万股
| 公告日期 | 2026-09-28 | 2026-09-28 | 2026-05-13 | 2026-05-13 | 2026-02-17 | 2026-02-17 |
|---|---|---|---|---|---|---|
| 证券总股本 | 3040.73 | 3240.70 | 3402.52 | 3515.60 | 3636.20 | 3664.70 |
| 普通股本 | 3040.73 | 3240.70 | 3402.52 | 3515.60 | 3636.20 | 3664.70 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-09-22 | 2026-06-30 | 2026-05-11 | 2026-03-31 | 2026-02-12 | 2025-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-09-28 | 3040.73 | 未披露 | 定期报告 | 2026-09-22 |
| 2026-09-28 | 3240.70 | 未披露 |
更多>>
From June 30, 2025 to June 30, 2026
Proceeds from the sale of Common Stock at $3.42 per share in July 2025, net of issuance costs
Issuance of Common Stock upon exercise of Pre-Funded Warrants for cash
Issuance of Common Stock upon cashless exercise of Pre-Funded Warrants
Issuance of Common Stock through our ATM, net of issuance costs
|
2026-06-30 |
| 2026-05-13 | 3402.52 | 未披露 | 定期报告 | 2026-05-11 |
| 2026-05-13 | 3515.60 | 未披露 |
更多>>
From December 31,2025 to March 31,2026
Issuance of Advisory Warrants in lieu of cash fees
|
2026-03-31 |
| 2026-02-17 | 3636.20 | 未披露 | 定期报告 | 2026-02-12 |
| 2026-02-17 | 3664.70 | 未披露 |
更多>>
From September 30, 2025 to December 31, 2025
Issuance of Common Stock upon cashless exercise of Pre-Funded Warrants
Repurchase of Common Stock
|
2025-12-31 |
| 2025-12-30 | 3676.97 | 未披露 | 定期报告 | 2025-12-15 |
| 2025-11-14 | 3678.54 | 未披露 | 定期报告 | 2025-11-08 |
| 2025-11-14 | 3565.50 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of Common Stock upon exercise of Pre-Funded Warrants for cash
Issuance of Common Stock upon cashless exercise of Pre-Funded Warrants
Proceeds from the sale of Common Stock at $342 per share in July 2025, net of issuance costs
Issuance of Common Stock through our ATM, net of issuance costs
|
2025-09-30 |
| 2025-09-26 | 3565.52 | 未披露 | 定期报告 | 2025-09-23 |
| 2025-08-26 | 3283.77 | 未披露 | 定期报告 | 2025-08-25 |
| 2025-08-06 | 3236.72 | 未披露 | 定期报告 | 2025-08-01 |
| 2025-07-22 | 2987.98 | 未披露 |
更多>>
The company issued 23,216,898 shares of common stock in the private placement
|
2025-07-22 |
| 2025-09-26 | 666.30 | 未披露 | 定期报告 | 2025-06-30 |
| 2025-05-13 | 666.29 | 未披露 | 定期报告 | 2025-05-02 |
| 2025-05-13 | 666.30 | 未披露 | 定期报告 | 2025-03-31 |
| 2025-02-12 | 666.29 | 未披露 | 定期报告 | 2025-02-07 |
| 2025-02-12 | 666.30 | 未披露 | 定期报告 | 2024-12-31 |
| 2024-11-12 | 666.29 | 未披露 | 定期报告 | 2024-11-08 |
| 2024-11-12 | 666.30 | 未披露 | 定期报告 | 2024-09-30 |
| 2024-09-19 | 666.29 | 未披露 | 定期报告 | 2024-09-13 |
| 2024-09-19 | 666.30 | 未披露 | 定期报告 | 2024-06-30 |
| 2024-05-09 | 666.29 | 未披露 | 定期报告 | 2024-05-06 |
| 2024-05-09 | 666.30 | 未披露 | 定期报告 | 2024-03-31 |
| 2024-02-13 | 666.29 | 未披露 | 定期报告 | 2024-02-09 |
| 2024-02-13 | 666.30 | 未披露 | 定期报告 | 2023-12-31 |
| 2023-11-08 | 666.29 | 未披露 | 定期报告 | 2023-10-19 |
| 2023-11-09 | 666.30 | 未披露 | 定期报告 | 2023-09-30 |
| 2023-09-26 | 666.29 | 未披露 | 定期报告 | 2023-09-15 |
| 2023-09-26 | 666.30 | 未披露 |
更多>>
From June 30, 2022 to June 30, 2023
Issuance of common stock for vested restricted stock units
|
2023-06-30 |
| 2023-04-28 | 666.29 | 未披露 | 定期报告 | 2023-04-23 |
| 2023-04-14 | 666.30 | 未披露 |
更多>>
MEI Pharma, Inc. announced that its board of directors approved a 1-for-20 reverse stock split.
|
2023-04-17 |
| 2023-02-09 | 13326.09 | 未披露 | 定期报告 | 2023-02-06 |
| 2023-02-09 | 13326.10 | 未披露 | 定期报告 | 2022-12-31 |
| 2022-11-14 | 13326.09 | 未披露 | 定期报告 | 2022-11-10 |
| 2022-11-14 | 13326.10 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock for vested restricted stock units
|
2022-09-30 |
| 2022-09-08 | 13326.09 | 未披露 | 定期报告 | 2022-09-07 |
| 2022-09-08 | 13315.20 | 未披露 |
更多>>
From June 30, 2021 to June 30, 2022
Issuance of common stock, net of issuance costs of 3,652,000
Issuance of common stock for vested restricted stock units
Exercise of stock options
|
2022-06-30 |
| 2022-05-23 | 13315.20 | 未披露 | 定期报告 | 2022-05-19 |
| 2022-05-23 | 13315.20 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Exercise of stock options
|
2022-03-31 |
| 2022-02-10 | 13298.55 | 未披露 | 定期报告 | 2022-02-08 |
| 2022-02-10 | 13290.50 | 未披露 |
更多>>
From September 30, 2021 to December 31, 2021
Issuance of common stock, net of issuance costs of $3,672
Exercise of stock options
|
2021-12-31 |
| 2021-12-06 | 13280.35 | 未披露 |
更多>>
1.MEI Pharma, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Wells Fargo Securities, LLC , as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale of 20,125,000 shares (the "Shares") of the Company's common stock, par value $0.00000002 per share ("Common Stock"), at a public offering price of $2.60 per share, which includes 2,625,000 shares of Common Stock sold as a result of the exercise by the underwriters of an option to purchase additional shares of Common Stock, pursuant to that certain Underwriting Agreement.The net proceeds to the Company from this offering are expected to be approximately $49,185,500, after deducting underwriting commissions and estimated offering expenses payable by the Company. The offering closed on December 6, 2021.
|
2021-12-06 |
| 2021-11-10 | 11272.12 | 未披露 | 定期报告 | 2021-11-08 |
| 2021-10-28 | 11270.52 | 未披露 | 定期报告 | 2021-10-20 |
| 2021-11-30 | 11267.85 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock for vested restricted stock units
|
2021-09-30 |
| 2021-09-02 | 11267.85 | 未披露 | 定期报告 | 2021-08-31 |
| 2021-09-02 | 11261.50 | 未披露 |
更多>>
From June 30, 2020 to June 30, 2021
Issuance of common stock, net
Exercise of warrants
Exercise of stock options
|
2021-06-30 |
| 2021-05-06 | 11259.18 | 未披露 | 定期报告 | 2021-05-04 |
| 2021-05-06 | 11259.20 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Exercise of warrants
Exercise of stock options
|
2021-03-31 |
| 2021-02-04 | 11252.79 | 未披露 | 定期报告 | 2021-02-02 |
| 2021-02-04 | 11252.80 | 未披露 |
更多>>
From September 30, 2020 to December 31, 2020
Exercise of stock options
|
2020-12-31 |
| 2020-11-10 | 11252.20 | 未披露 | 定期报告 | 2020-11-06 |
| 2020-10-27 | 11252.20 | 未披露 | 定期报告 | 2020-10-20 |
| 2020-11-10 | 11252.20 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock
Exercise of stock options
|
2020-09-30 |
| 2020-09-09 | 11252.20 | 未披露 | 定期报告 | 2020-09-03 |
| 2020-09-09 | 11151.40 | 未披露 |
更多>>
From June 30, 2019 to June 30, 2020
Issuance of common stock, net
Exercise of stock options
|
2020-06-30 |
| 2020-05-07 | 10599.87 | 未披露 | 定期报告 | 2020-05-04 |
| 2020-05-07 | 10599.90 | 未披露 | 定期报告 | 2020-03-31 |
| 2020-02-06 | 10599.87 | 未披露 | 定期报告 | 2020-02-03 |
| 2020-02-06 | 10599.90 | 未披露 |
更多>>
From September 30, 2019 to December 31, 2019
Issuance of common stock
|
2019-12-31 |
| 2019-12-19 | 10177.99 | 未披露 |
更多>>
1.Common stock offered by us pursuant to this prospectus supplement 28,125,000 shares of common stock
2.Based on 73,654,927 shares of common stock outstanding as of November 30, 2019
|
2019-12-19 |
| 2019-10-23 | 7365.49 | 未披露 | 定期报告 | 2019-10-09 |
| 2019-11-07 | 7365.50 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Issuance of common stock
Exercise of stock options
|
2019-09-30 |
| 2019-08-28 | 7363.49 | 未披露 | 定期报告 | 2019-08-26 |
| 2019-08-28 | 7354.50 | 未披露 |
更多>>
From June 30, 2018 to June 30, 2019
Exercise of stock options
Issuance of common stock
Exercise of warrants
Issuance of common stock for vested restricted stock units
|
2019-06-30 |
| 2019-05-09 | 7129.05 | 未披露 | 定期报告 | 2019-05-06 |
| 2019-05-09 | 7128.10 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Exercise of stock options
|
2019-03-31 |
| 2019-02-07 | 7114.91 | 未披露 | 定期报告 | 2019-02-05 |
| 2019-02-07 | 7113.10 | 未披露 | 定期报告 | 2018-12-31 |
| 2018-11-30 | 7111.54 | 未披露 | 定期报告 | 2018-11-29 |
| 2018-11-08 | 7112.54 | 未披露 | 定期报告 | 2018-11-06 |
| 2018-10-11 | 7111.54 | 未披露 | 定期报告 | 2018-10-03 |
| 2018-11-08 | 7111.50 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-30 | 7108.64 | 未披露 | 定期报告 | 2018-08-27 |
| 2018-08-30 | 7040.60 | 未披露 |
更多>>
from June 30, 2017 to June 30, 2018
Issuance of common stock in private placement
Issuance of common stock for milestone payment
Issuance of common stock for vested restricted stock units
Exercise of stock options
|
2018-06-30 |
| 2018-06-06 | 7032.67 | 未披露 | 定期报告 | 2018-06-05 |
| 2018-05-09 | 3732.34 | 未披露 | 定期报告 | 2018-05-08 |
| 2018-05-09 | 3732.30 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-02-08 | 3705.24 | 未披露 | 定期报告 | 2018-02-06 |
| 2018-02-08 | 3705.20 | 未披露 | 定期报告 | 2017-12-31 |
| 2017-11-08 | 3701.49 | 未披露 | 定期报告 | 2017-11-06 |
| 2017-10-16 | 3695.02 | 未披露 | 定期报告 | 2017-10-04 |
| 2017-11-08 | 3695.00 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-09-05 | 3693.90 | 未披露 | 定期报告 | 2017-08-30 |
| 2017-09-05 | 3677.20 | 未披露 |
更多>>
from June 30, 2016 to June 30, 2017
Issuance of common stock
|
2017-06-30 |
| 2017-05-04 | 3677.24 | 未披露 | 定期报告 | 2017-03-31 |
| 2016-09-06 | 3677.24 | 未披露 | 定期报告 | 2016-08-31 |
| 2012-12-19 | 1370.00 | 未披露 |
更多>>
a 1 for 6 split of it's common stock
|
2012-12-19 |
| 2012-11-13 | 2167.35 | 0.10 | 定期报告 | 2012-09-30 |
| 2012-09-18 | 2167.35 | 未披露 | 定期报告 | 2012-09-17 |
| 2012-09-18 | 2049.89 | 0.10 |
更多>>
from June 30, 2011 to June 30, 2012
Issuance of common stock
|
2012-06-30 |
| 2012-05-15 | 2049.89 | 未披露 | 定期报告 | 2012-05-15 |
| 2012-02-09 | 1466.87 | 0.10 | 定期报告 | 2011-12-31 |
| 2011-11-14 | 1181.40 | 0.10 | 定期报告 | 2011-09-30 |
| 2011-09-28 | 1017.51 | 未披露 | 定期报告 | 2011-09-15 |
| 2011-09-28 | 888.11 | 0.10 |
更多>>
from June 30,2010 to June 30,2011
Issuance of preferred stock
|
2011-06-30 |
| 2008-09-15 | 7346.32 | 未披露 | 定期报告 | 2008-09-10 |
| 2007-09-27 | 6885.49 | 未披露 | 定期报告 | 2007-08-31 |
| 2006-09-01 | 6339.09 | 未披露 | 定期报告 | 2006-08-31 |
From June 30, 2025 to June 30, 2026
Proceeds from the sale of Common Stock at $3.42 per share in July 2025, net of issuance costs
Issuance of Common Stock upon exercise of Pre-Funded Warrants for cash
Issuance of Common Stock upon cashless exercise of Pre-Funded Warrants
Issuance of Common Stock through our ATM, net of issuance costs
From December 31,2025 to March 31,2026
Issuance of Advisory Warrants in lieu of cash fees
From September 30, 2025 to December 31, 2025
Issuance of Common Stock upon cashless exercise of Pre-Funded Warrants
Repurchase of Common Stock
From June 30, 2025 to September 30, 2025
Issuance of Common Stock upon exercise of Pre-Funded Warrants for cash
Issuance of Common Stock upon cashless exercise of Pre-Funded Warrants
Proceeds from the sale of Common Stock at $342 per share in July 2025, net of issuance costs
Issuance of Common Stock through our ATM, net of issuance costs
The company issued 23,216,898 shares of common stock in the private placement
From June 30, 2022 to June 30, 2023
Issuance of common stock for vested restricted stock units
MEI Pharma, Inc. announced that its board of directors approved a 1-for-20 reverse stock split.
From June 30, 2022 to September 30, 2022
Issuance of common stock for vested restricted stock units
From June 30, 2021 to June 30, 2022
Issuance of common stock, net of issuance costs of 3,652,000
Issuance of common stock for vested restricted stock units
Exercise of stock options
From December 31, 2021 to March 31, 2022
Exercise of stock options
From September 30, 2021 to December 31, 2021
Issuance of common stock, net of issuance costs of $3,672
Exercise of stock options
1.MEI Pharma, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Wells Fargo Securities, LLC , as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale of 20,125,000 shares (the "Shares") of the Company's common stock, par value $0.00000002 per share ("Common Stock"), at a public offering price of $2.60 per share, which includes 2,625,000 shares of Common Stock sold as a result of the exercise by the underwriters of an option to purchase additional shares of Common Stock, pursuant to that certain Underwriting Agreement.The net proceeds to the Company from this offering are expected to be approximately $49,185,500, after deducting underwriting commissions and estimated offering expenses payable by the Company. The offering closed on December 6, 2021.
From June 30, 2021 to September 30, 2021
Issuance of common stock for vested restricted stock units
From June 30, 2020 to June 30, 2021
Issuance of common stock, net
Exercise of warrants
Exercise of stock options
From December 31, 2020 to March 31, 2021
Exercise of warrants
Exercise of stock options
From September 30, 2020 to December 31, 2020
Exercise of stock options
From June 30, 2020 to September 30, 2020
Issuance of common stock
Exercise of stock options
From June 30, 2019 to June 30, 2020
Issuance of common stock, net
Exercise of stock options
From September 30, 2019 to December 31, 2019
Issuance of common stock
1.Common stock offered by us pursuant to this prospectus supplement 28,125,000 shares of common stock
2.Based on 73,654,927 shares of common stock outstanding as of November 30, 2019
From June 30, 2019 to September 30, 2019
Issuance of common stock
Exercise of stock options
From June 30, 2018 to June 30, 2019
Exercise of stock options
Issuance of common stock
Exercise of warrants
Issuance of common stock for vested restricted stock units
from December 31, 2018 to March 31, 2019
Exercise of stock options
from June 30, 2017 to June 30, 2018
Issuance of common stock in private placement
Issuance of common stock for milestone payment
Issuance of common stock for vested restricted stock units
Exercise of stock options
from June 30, 2016 to June 30, 2017
Issuance of common stock
a 1 for 6 split of it's common stock
from June 30, 2011 to June 30, 2012
Issuance of common stock
from June 30,2010 to June 30,2011
Issuance of preferred stock